Molbio Diagnostics Ltd. Share Price

Molbio Diagnostics Ltd Company FUndamental Analysis

Molbio Diagnostics is a healthcare technology company specialising in point-of-care molecular diagnostics through its proprietary Truenat platform. Its portable, battery-operated PCR systems enable rapid testing for infectious diseases, including tuberculosis, in hospitals, laboratories and remote healthcare settings. The company has an international footprint, with more than 12,500 Truenat devices deployed across 90+ countries. Its growth strategy includes expanding test-kit consumption, entering new markets and developing additional assays for diseases beyond infectious conditions. FY26 consolidated revenue increased to approximately ₹1,445.7 crore from ₹1,020.4 crore in FY25, while PAT rose to ₹164.1 crore from ₹138.6 crore. Q1 FY27 total income reached ₹411.5 crore, compared with ₹100.5 crore in Q1 FY26, while EBITDA improved to ₹103.7 crore from a loss of ₹14.5 crore and PAT reached ₹52.7 crore versus a loss of ₹23.9 crore. However, management noted that approximately ₹57 crore of export orders delayed from Q4 FY26 were recognised in Q1 FY27, and that quarterly revenue can be uneven. At approximately ₹1,472, Molbio's market capitalisation was about ₹16,631 crore, with a P/E of 101.3x, P/B of 12.1x and ROE of 14.25%, according to Groww's latest displayed data. The long-term opportunity lies in higher test-kit consumption, expansion into Africa, Southeast Asia and Latin America, and its pipeline of 34 assays covering 22 diseases. However, valuation is demanding, while revenue concentration is a key risk: around 80% of FY26 revenue came from government-related business and approximately 70% from tuberculosis testing. Overall, Molbio has differentiated technology, a global distribution opportunity and substantial operating leverage, but sustained growth beyond tuberculosis, diversification of customers and consistent cash generation will be crucial to justify its premium valuation.

See More

Molbio Diagnostics Ltd Company Fundamental Analysis

Molbio Diagnostics is a molecular point-of-care diagnostics company built around its proprietary Truenat platform, a portable PCR-based system designed for decentralised testing. As of March 2026, the platform covered 30 diseases through 43 assays, including tuberculosis, HIV, hepatitis and HPV, while the company has also expanded into radiology, digital pathology and breast-health screening. Truenat's patents across more than 100 countries and its positioning for resource-constrained healthcare settings provide meaningful entry barriers. FY26 revenue from operations increased 41.7% to ₹1,445.6 crore, EBITDA rose 27.9% to ₹328.2 crore and PAT increased 18.4% to ₹164.1 crore. Q1 FY27 showed a much sharper recovery, with revenue reaching ₹411.5 crore versus ₹100.5 crore a year earlier, EBITDA of ₹103.7 crore versus a ₹14.5 crore loss and PAT of ₹52.7 crore versus a ₹23.9 crore loss. Operating margin was 25.4%, indicating a substantial improvement in profitability. The key growth drivers are increasing molecular-testing adoption, expansion of Truenat assays, international penetration, higher test-kit consumption and investments in R&D and manufacturing capacity. However, concentration is an important risk: around 80% of FY26 revenue reportedly came from the B2G segment and around 70% from TB testing, making government programmes and TB-related demand significant dependencies. Therefore, while the business has strong technology, improving profitability and substantial growth potential, the current valuation already discounts considerable future growth. Sustaining earnings growth while reducing customer/product concentration will be crucial to justify the premium valuation.

See More

Molbio Diagnostics is in the spotlight this week

Molbio Diagnostics is in the spotlight this week: the company reported its first-ever EBITDA and PAT profitability in FY27, driven by strong adoption of its Truenat diagnostic platform, while HDFC Mutual Fund acquired a 1.99% stake worth ₹302 crore, boosting investor confidence. 📊 Key Financial Updates Q1 FY27 Results (June 2026): Revenue: ₹411.48 crore (up from ₹100.47 crore YoY, though down 27.2% QoQ). EBITDA: ₹103.68 crore (vs. a ₹14.5 crore loss last year). PAT: ₹52.74 crore (vs. a ₹23.94 crore loss last year). Operating Margin: 20.4% (vs. -27.7% YoY). EPS: ₹5.21 (vs. -₹2.10 YoY). Revenue Mix: 75% from recurring test-kit sales, showing a shift to a sustainable, volume-led model. Market Cap: ~₹14,765 crore. Debt/Equity Ratio: 0.35 (low leverage). 📈 Stock Market Developments HDFC Mutual Fund Bulk Deal (1 Oct 2026): Bought 23 lakh shares (1.99% stake) at ₹1,315/share. Deal value: ₹302.45 crore. Seller: Business Excellence Trust III (Motilal Oswal PE), trimming its stake by ~2%. Share Price Movement: Rose 5% on 1 Oct 2026 after the deal. Current price: ~₹1,313–₹1,315. IPO (Aug 2026): ₹807 → Listing at ₹980. 52-week high: ₹1,686.80. Jefferies has a Buy rating with a target of ₹1,600 (27% upside from late September close).

See More

Why Molbio was up 15% — key fundamental triggers

Why Molbio was up 15% — key fundamental triggers 1. HDFC Mutual Fund bought ~2% stake — major immediate trigger HDFC Mutual Fund bought around 23 lakh shares, equivalent to 1.99% of Molbio, in a bulk deal worth roughly ₹302 crore, at about ₹1,315/share. This institutional buying was a major positive sentiment trigger for the stock. 2. Jefferies initiated coverage with ₹1,600 target Just one day earlier, Jefferies initiated coverage on Molbio with a Buy view and a ₹1,600 target. Jefferies highlighted Molbio's Truenat platform, its international opportunity and its pipeline of new products. The brokerage estimates FY26–FY29 revenue CAGR of ~22% and PAT CAGR of ~47%, with margin expansion driven by higher capacity utilisation and operating leverage. These are brokerage estimates, not company guidance. 3. Strong Q1 FY27 financial performance supports the story Molbio's Q1 FY27 consolidated numbers showed a sharp turnaround: Total income: ₹411.5 crore vs ₹100.5 crore YoY EBITDA: ₹103.7 crore vs ₹14.5 crore loss PAT: ₹52.7 crore vs ₹23.9 crore loss EBITDA margin: 25.2% The company attributed the growth primarily to higher Truenat test-kit consumption. 4. Truenat has a sizeable international installed base The company says more than 12,500 Truenat devices had been installed across 90+ countries as of March 2026. It is also expanding internationally in Africa, Southeast Asia and Latin America, while pursuing regulatory pathways in developed markets. 5. Product pipeline provides a longer-term growth narrative Molbio says it has 34 additional assays across 22 diseases in its pipeline, while expanding beyond infectious diseases into areas such as oncology and other non-communicable diseases.

See More

molecular diagnostics, led by the Truenat platform.

Strengths Truenat is a portable real-time PCR platform designed for point-of-care testing and multiple infectious diseases. Installed base of roughly 12,500 devices across 90+ countries, creating a recurring consumables opportunity. Test-kit consumption is a major revenue driver; around 62.4 lakh kits were sold in Q1 FY27. Weaknesses Revenue can be non-linear and volatile because public-health programmes and government orders can shift between quarters. Management specifically highlighted this characteristic. International expansion requires continued investment in sales and market development. Dependence on the Truenat ecosystem creates concentration around one major technology platform. New products and overseas businesses require regulatory approvals and commercial ramp-up. Q1 FY27 revenue from operations was about ₹408 Cr, while consolidated debt stood around ₹413 Cr at FY26-end according to third-party financial data. Opportunities Expansion of TB testing across underserved diagnostic centres. Potential growth from HPV screening, with management discussing rollout following validation/approval processes. International expansion across the US, Europe and other emerging markets. Growth in recurring test-kit consumption as the installed device base increases. OptraScan provides an additional digital pathology/diagnostics opportunity; management expects more meaningful contribution beyond FY27. Expansion into additional infectious-disease assays and decentralised healthcare. Threats Competition from global molecular-diagnostics companies. Regulatory and product-approval risks in international markets. Government procurement and public-health programme changes can affect quarterly revenue. Pricing pressure on diagnostic kits. Rapid technological developments could require continuous R&D investment. Customer/geographic concentration could increase earnings volatility.

See More

Molbio Diagnostics Ltd Company Fundamental Analysis

Molbio Diagnostics is a molecular diagnostics company focused on decentralised point-of-care testing, with its flagship Truenat platform offering portable, battery-powered PCR testing for infectious and non-communicable diseases. The business has a differentiated product ecosystem covering analysers, test kits and associated consumables, with recurring demand from test-kit usage. Its technology is particularly relevant for settings where centralised laboratory infrastructure is limited. The business delivered a sharp recovery in Q1 FY27. Consolidated total income increased to ₹411.5 crore from ₹100.5 crore in Q1 FY26, while EBITDA moved from a ₹14.5 crore loss to ₹103.7 crore, giving a 25.2% EBITDA margin. PAT improved from a ₹23.9 crore loss to ₹52.7 crore. The company highlighted continued growth in Truenat test-kit consumption as a key driver. FY26 revenue was approximately ₹1,446 crore, with ROE around 15% and ROCE around 18–20%. However, operating cash flow and working-capital requirements remain areas worth monitoring as the business scales. Growth opportunities include greater adoption of molecular testing, expansion into international markets, increasing test-kit consumption and utilisation of recently expanded manufacturing and R&D capacity. The IPO proceeds are also being deployed toward R&D/Center of Excellence infrastructure and additional plant and machinery. At the latest Groww snapshot, market capitalisation was around ₹14,361 crore, P/E 87.5x, P/B 10.5x, ROE 14.25% and debt-to-equity 0.38x. The major risks are high valuation relative to current earnings, dependence on Truenat adoption and public-health/export orders, execution of capacity expansion and potentially uneven quarterly revenue due to order timing. The recent turnaround in profitability is significant, but sustaining high growth and improving capital efficiency will be important for the business to justify its current valuation.

See More